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Abstract 
Microparticles (MPs) are small membrane-vesicles that accumulate in the synovial fluids of 
patients with rheumatoid arthritis (RA). In the arthritic joints, MPs induce a pro-inflammatory 
and invasive phenotype in synovial fibroblasts (SFs). The present study investigated whether 
activation of SFs by MPs stimulate angiogenesis in the inflamed joints of patients with RA. 
MPs were isolated from Jurkat cells and U937 cells by differential centrifugation. SFs were 
co-cultured with increasing numbers of MPs. The effects of supernatants from co-cultures on 
endothelial cells were studied in vitro and in vivo using MTT assays, annexin V and 
propidium iodide staining, trans-well migration assays, and modified matrigel pouch assays.  
MPs strongly induced the expression of the pro-angiogenic ELR+ chemokines CXCL1, 
CXCL2, CXCL3, CXCL5, and CXCL6 in SFs. Other vascular growth factors were not 
induced. Supernatants from co-cultures enhanced the migration of endothelial cells, which 
could be blocked by neutralizing antibodies against ELR+ chemokines. Consistent with the 
specific induction of ELR+ chemokines, proliferation and viability of endothelial cells were 
not affected by the supernatants. In the in vivo bio-chamber assay, supernatants from SFs co-
cultured with MPs stimulated angiogenesis with a significant increase of vessels infiltrating 
into the matrigel chamber.  
We demonstrated that MPs activate SFs to release pro-angiogenic ELR+ chemokines. These 
pro-angiogenic mediators enhance migration of endothelial cells and stimulate the formation 
of new vessels. Our data suggest that MPs may contribute to the hypervascularization of 
inflamed joints in patients with rheumatoid arthritis. 
Introduction 
 Rheumatoid Arthritis (RA) is a chronic autoimmune disease that causes inflammation 
and destruction of synovial joints in association with extra-articular manifestations. RA 
synovial fibroblasts (RASF) are key players in the pathogenesis of RA. RASF display an 
invasive and pro-inflammatory phenotype with invasion into cartilage and aberrant release of 
pro-inflammatory mediators [1,2]. RASFs also stimulate the generation of new blood vessels 
by releasing pro-angiogenic mediators [3,4]. The enhanced vascularisation of the hyperplastic 
synovium is considered a crucial step in disease progression, since it supports the influx of 
more immune cells via these newly formed blood vessels [5].  
MPs have recently been implicated in the pathogenesis of RA. Leukocyte derived 
MPs, which are released from their parental cells upon cellular activation and during 
apoptosis, accumulate in the synovial fluid of inflamed joints [6,7]. Indeed, high numbers of 
leukocyte derived MPs are found in the synovial fluid of swollen joints from RA patients, 
whereas MPs counts are low in OA joints with less acute inflammation [8-12].  MPs are small 
membrane-vesicles that act as signaling elements in coagulation, inflammation, and 
angiogenesis. Once released by cell blebbing and shedding, MPs can transfer lipids, proteins, 
and nucleic acids, as well as activate intracellular pathways in target cells. Content and 
function of MPs depend on both the paternal cell and on the stimulus for MP release. During 
MP formation, selective rearrangement processes result in MP subpopulations specific for 
membrane and intra-vesicular content. Thus, MPs can operate selectively in intercellular 
communication and orchestrate biological processes [13]. MPs can induce pro-inflammatory 
and invasive properties in RASF, leading to joint inflammation and destruction. We 
demonstrated previously that MPs provide a source of arachidonic acids and up-regulate 
cyclooxygenase 2 (COX-2) and microsomal prostaglandin E synthase 1 (mPGES-1) in SFs, 
which subsequently convert arachidonic acid to prostaglandin E2 (PGE2) [14]. MPs from 
T cells and monocytes stimulate the expression of pro-inflammatory cytokines in SFs, 
including monocyte chemoattractant protein-1 (MCP-1) as well as interleukins 6 and 8 [15]. 
Beyond their pro-inflammatory effects in RA joints, MPs can induce the release of matrix 
metalloproteinases (MMPs)-1, -3, -9, and -13 from SFs, and thus, promote cartilage 
breakdown and joint destruction [15].   
 Early studies found that synovial fluids from patients with RA stimulate the 
formation of blood vessels, suggesting the presence of pro-angiogenic mediators in the joints 
[16-18]. Based the potent induction of pro-inflammatory mediators and MMPs in RASF by 
MPs, we hypothesized that MPs might also stimulate angiogenesis and contribute to the 
hypervascularisation of the synovial tissue in inflamed RA joints. We could demonstrate that 
MPs derived from leukocytes potently induce the expression of ELR+ chemokines in RASF 
and that MPs induced ELR+ chemokines stimulate angiogenesis by providing a chemotactic 
gradient for endothelial cells (ECs).  
 
Material and methods 
Cell culture 
SFs were isolated from synovial tissue specimens from 9 patients with rheumatoid 
arthritis (RA) [19]. All RA patients fulfilled the American College of Rheumatology 1987 
revised criteria for the classification of RA. The clinical characteristics of these patients are 
summarized in table 1. 
Murine synovial fibroblasts were derived from 8 weeks old female C57Bl/6 mice. 
Paws and joints were minced and digested in 0.5 % dispase [20]. 
Immortalized human microvascular endothelial (HMECs) cells were cultured as 
described elsewhere [21]. 
 
Isolation of MPs and incubation of fibroblasts and HMECs 
The release of MPs from Jurkat T cells and U937 monocytic cells was induced by 
treatment with staurosporine (STS, Sigma Aldrich, Munich, Germany) and TNFα (R&D 
systems, Wiesbaden, Germany) as described previously [22]. After 12 hours of treatment, 
supernatants were collected and centrifuged at 1500 g for 5 min to remove cells. The cell-free 
supernatants were centrifuged at 100.000 g and 14 °C for 40 min using a Beckman Coulter 
LE-80K ultracentrifuge with a SW41 rotor. After another washing step, the pellet was 
resuspended in DMEM/F-12 containing 5 % fetal bovine serum (FBS).  
  For co-culture experiments, 5.0 x 105 fibroblasts were incubated with 1.0 x 104 to 1.0 x 
106 freshly isolated MPs. Supernatants of the first ultracentrifugation step served as controls 
and were therefore processed in the same way as the MP-pellets. Consequently, control 
supernatants without MPs contained the same concentrations of soluble mediators as the MP 
suspensions. After 24 h of incubation, the supernatant of the coculture experiments or control 
experiments was removed and filtered through 0.1 µm pores to remove the remaining MPs. 
The MP-free supernatants were then used immediately to assess their effects on endothelial 
cell functions and angiogenesis.  
 
Quantification of MPs 
  To determine the numbers of MPs, freshly isolated preparations were incubated with 
FITC-labeled antibodies against human CD3 or CD14 and double-stained with PE-labeled 
annexin V (all Becton Dickinson, Heidelberg, Germany) as described [15].  
 
Quantitative real-time PCR   
 Total RNA was isolated with the NucleoSpin RNA extraction system (Machery-
Nagel, Düren, Germany). RNA was reverse transcribed into cDNA and gene expression was 
quantified by TaqMan and SYBR Green real-time PCR using the ABI Prism 7300 Sequence 
Detection System (Applied Biosystems, Darmstadt, Germany) [23]. Specific primers for each 
gene were designed with the Primer 3 software. Primer sequences are summarized in table 2. 
Samples without enzyme in the reverse transcription (Non-RT-controls) were used to control 
for genomic contamination. Unspecific signals caused by primer dimers were excluded by 
dissociation curve analysis and by no template controls. A predeveloped 18S assay (Applied 
Biosystems) was used as an endogenous control to normalize for the amounts of loaded 
cDNA. Differences were calculated with the threshold cycle (Ct) and the comparative Ct 
method. 
 
Transwell migration assays  
The effect of supernatants from fibroblasts co-incubated with MPs on endothelial cell 
migration was analyzed by transwell migration assays. Cell culture inserts with 8 µm pore-
size polyethylene terephthalate (PET) membranes were placed into 24-well cell cultured 
dishes. The lower chamber was filled with 500 µl of supernatants from fibroblasts co-
incubated with MPs in different dilutions. 2 x 104 HMECs in 200 µl DMEM/F-12 containing 
5 % FBS were seeded. After 24 h, the migration of HMECs across the membrane was 
analyzed by counting the HMECs in the lower chamber using flow cytometry (BD FACS-
Calibur, Becton Dickinson, Heidelberg, Germany).  
To identify stimuli for increased migration, neutralizing antibodies against pro-
angiogeneic CXC chemokines were added in a subset of experiments. In these experiments, 
supernatants were pre-incubated with neutralizing antibodies against GROα / β/ γ, ENA78 or 
GCP-2 (all R&D Systems, Wiesbaden, Germany) for 2 h at 37 °C.  
 
Quantification of apoptotic and necrotic cells 
To analyze potential effects on the viability of endothelial cells, HMECs were 
incubated for 24 h with different concentrations of supernatants from SFs co-cultured with 
MPs. HMECs were stained with FITC labeled annexin V and propicium iodide and cell 
viability was assessed with FACS as described [24].  
 
Microtiter tetrazolium (MTT) assay 
Metabolic activity of HMECs incubated with the SF and MPs co-culture supernatants 
was measured using the MTT [3, (4, 5-dimethylthiazol-2-yl) 2, 5-diphenyl-tetrazolium 
bromide] method as described [24]. HMECs incubated with 50 % DMSO served as positive 
controls. 
 
In vivo Matrigel-plug assay  
The effects of supernatants from SF incubated with MPs on angiogenesis were 
analyzed in vivo using a modified matrigel-plug assay [25]. Matrigel chambers were 
constructed using 3 mm sections of surgical grad tubing (Tygon S-50-HL, Saint-Gobain, 
Akron, USA) and 100 µm nylon filters that were attached at both end of the tubes. Chambers 
were sterilized by UV irradiation. Three ml of supernatant from coculture experiments of SF 
with MPs was evaporated, re-suspended in 100 µl liquid matrigel and injected into each 
chamber. Chambers with equally concentrated supernatants from SF cultured without MPs 
served as controls. For implantation of the chambers, eight week old, female C57Bl/6 mice 
mice were anesthetized and a 1 cm incision was made along the medial plane in the pectoral 
region. The chambers were inserted into subcutaneous pockets at the midline in the pelvic 
region 1.5 cm distal to the incision, which was closed using 9 mm stainless steel wound clips. 
Eight mice were implanted with two chambers each, one on the left flank and one on the right 
flank. In each mouse, one chamber contained supernatants from SF co-incubated with MPs 
and the second chamber contained control supernatants. Ten days after the implantation, the 
chambers were removed, fixed in 10 % paraformaldehyde for 24 h and then embedded in 
paraffin. Two µm thick sections of six different layers of the plaque were stained with 
hematoxylin and eosin. Numbers of blood vessels were analyzed with a Nikon Eclipse 80i 
microscope (Nikon, Badhoevedorp, Netherlands) at 200 fold magnification.  
 
Immunohistochemistry for CD34 
Immunohistochemistry for CD34 was used to visualize endothelial cells in chambers 
of Matrigel-plug assay. Two µm thick sections of plugs were deparaffinized, following by 
treatment with 1 mg/ml trypsin (Sigma, Munich, Germany) for 1 h at 37 °C. Non-specific 
binding of antibody was blocked by incubation with 5 % goat serum in PBS for 30 min at 
room temperature and endogenous peroxidase activity was blocked by incubation with 3 % 
H2O2 for 10 min at room temperature. Endothelial cells were detected by incubation with 
polyclonal rat anti-mouse CD34 antibody (Linaris, Wertheim-Bettingen, Germany) for 2 h at 
room temperature. Polyclonal goat anti-rat antibody (Abcam, Cambridge, UK) labeled with 
horseradish peroxidase was used as secondary antibody for 1 h at room temperature. Staining 
was visualized with 3,3´diaminobenzidine tetradydrochloride (DAB, Merck, Darmstadt, 
Germany).  
 
Statistics 
Data are expressed as mean ± standard error of the mean. The Wilcoxon signed rank 
test for related samples and the Mann-Whitney test for non-related samples were used for 
statistical analyses. A p-value of less than 0.05 was considered statistical significant. 
Results 
MPs induce the release of pro-angiogenic chemokines in synovial fibroblasts 
 Coincubation with MPs from TNFα stimulated U937 cells potently induced the 
expression of members of the ELR+ subfamily of CXC chemokines in SFs. The mRNA levels 
of CXCL1 (GROα), CXCL2 (GROβ) and CXCL3 (GROγ) increased in a dose-dependent 
manner by up to 180 ± 32 fold, 31 ± 7 fold, and 250 ± 42 fold, in RASF compared to controls 
(p < 0.05 for all) (Figures 1 a – c). A significant induction of up to 150 ± 16 fold was also 
observed for CXCL5 (ENA-78) (Figures 1 d). CXCL6 (GCP-2) was also upregulated by 551 
± 95 fold in RASF co-incubated with MPs (p = 0.02) (Figures 1 e and f). Comparable effects 
of MPs on the mRNA levels of ELR+ chemokines were also observed with OASF (Figures 1 
a-f). In addition to MPs derived from U937 monocytic cells, MPs from apoptotic Jurkat T 
cells also potently stimulated the expression of ELR+ chemokines, indicating a general effect 
of leukocyte derived MPs. To confirm the relevance of these findings with MPs from U937- 
and Jurkat cell lines, MPs were isolated from the synovial fluid of inflamed RA joints. MPs 
isolated from synovial fluid potently increased the mRNA levels of CXCL-1, CXCL-2, 
CXCL-3, CXCL-5 and CXCL-6 (Figures 1…). Indeed, the increased were comparable to 
those obtained with MPs from U937 and Jurkat T cell lines, indicating that MPs from these 
cells are a good model to study the effects of leucocyte derived MPs on RASF.  
 
Supernatants from SFs co-incubated with MPs are chemotactic for endothelial cells 
 To investigate, whether the induction of ELR+ chemokines in RASFs by MPs is 
sufficient to induce endothelial cell migration, transwell chamber assays were performed. 
Supernatants from RASFs co-incubated with MPs induced the migration of endothelial cells. 
The number of HMECs that migrated into the lower chambers of the transwell towards the 
supernatants from co-culture experiments with MPs system increased by 7.2 ± 2.3 fold 
compared to control supernatants from RASFs cultured without MPs (p = 0.01) (Figure 2). 
To confirm, the increased migration is indeed due to the induction of ELR+ 
chemokines, the supernatants from the co-cultured experiments were pre-incubated with 
neutralizing antibodies against different ELR+ chemokines in a subset of experiments. 
Neutralizing antibodies against the GRO subfamily (CXCL1, CXCL2 and CXCL 3) reduced 
the stimulatory effects of supernatants from SF co-cultured with MPs by 35 ± 23 % (p = 0.04) 
(Figure 2). Neutralization of CXCL5 and CXCL6 also significantly decreased the stimulatory 
effects by 57 ± 35 % for CXCL5 and 57 ± 35 % for CXCL6 (p = 0.04 for both).  
 
Supernatants from RASFs co-cultured with MPs do not affect proliferation or viability 
of endothelial cells 
 To investigate, whether supernatants from RASFs co-incubated with MPs also alter 
proliferation or survival in addition to migration, the metabolic activity and the viability of 
endothelial cells upon co-culture were assessed. Incubation of HMECs with supernatant from 
RASFs co-cultured with MPs did not alter the proliferation of HMECs (Figure 3 a). 
Incubation of HMECs with supernatants from RASFs co-incubated with MPs also did not 
alter the number of apoptotic or necrotic cells as analyzed by staining with annexin V and 
propidiumiodide (Figure 3 b and 3 c), suggesting that co-incubation of RASFs with MPs 
might specifically stimulate the release of ELR+ chemokines, but not of endothelial growth 
factors that stimulate proliferation or decrease apoptosis. Consistent with this hypothesis, no 
induction of major endothelial growth factors such as vascular endothelial growth facor 
(VEGF), basic fibroblast growth factor (bFGF) and angiogenin was observed in SF upon 
coculture with MPs (data not shown). 
 
Supernatants from fibroblasts co-incubated with MPs stimulate angiogenesis in vivo 
  To confirm the chemotactic and pro-angiogenic effects of supernatants from RASFs 
co-incubated with MPs in vivo, modified matrigel chamber assays were performed. The total 
number of vessels, defined by the presence of erythrocytes in the luminal space lined by 
CD34 positive endothelial cells, increased significantly by 2.0 ± 0.6 fold in chambers filled 
with supernatants from RASFs co-incubated with MPs compared to supernatants from RASFs 
cultured without MPs (p = 0.03) (Figure 4). Further sub-analyses demonstrated that the 
numbers of arterioles and capillaries were both higher, but that the increase in arterioles was 
more pronounced than in capillaries (2.1 ± 0.7 fold vs. 1.5 ± 0.5 fold).   
Discussion 
 Our study provides new insights into the mechanisms by which MPs activate RASFs 
and extend previous results demonstrating that MPs play important roles in the pathogenesis 
of RA. MPs upregulate the expression of pro-inflammatory cytokines and prostaglandin E2 by 
synovial fibroblasts [8,14,15]. Moreover, MPs stimulate the expression of matrix degrading 
enzymes by SF [15]. Besides inflammation and joint destruction, increased angiogenesis with 
increased formation of new vessels in inflamed joints is a key-feature of the pathogenesis of 
RA [27]. Here, we show that MPs might also stimulate angiogenesis by inducing the release 
of ELR+ chemokines. MPs are released from activated leukocytes in inflamed RA joints and 
accumulate in  high numbers in the synovial fluid of patients with active RA [9]. In contrast, 
MP counts are low in patients with degenerative joint diseases such as OA [6,9,26]. Thus, the 
release of pro-angiogenic chemokines and the other actions of MPs on SF are operative only 
in inflammatory joint diseases such as RA, but not in non-inflammatory degenerative diseases 
[26]. Together, these findings demonstrate that MPs are novel signaling elements in RA 
which, along with cytokines and direct cell-cell interactions, can activate SF to promote local 
inflammation, matrix degradation and angiogenesis in affected joints (Figure 5). 
  In the present study, we have demonstrated the MPs potently stimulate the release of 
pro-angiogenic ELR+ chemokines by SF. MPs upregulated the expressions of CXCL1, 
CXCL2, CXCL3, CXCL5 and CXCL6 by up to 550 fold in SF. The induction was specific 
for ELR+ chemokines and other vascular growth factors were not induced. Supernatants from 
fibroblasts co-incubated with MPs induce angiogenesis in in-vivo matrigel plaque assays, 
indicating that the mediators released from SF upon contact with MPs alone are sufficient to 
stimulate angiogenesis in vivo. Thus, the massive induction of ELR+ chemokines might 
create a chemotactic gradient within inflamed joints that attracts endothelial cells and 
stimulates the formation of new vessels in affected joints.  
 In summary, we have demonstrated in this study that MPs stimulate the release of pro-
angiogenic ELR+ chemokines in SF by MP. The release of ELR+ chemokines attracts 
endothelial cells along a chemotactic gradient. The release of ELR+ chemokines upon by SF 
upon contact with MPs is sufficient to stimulate angiogenesis in vivo and may contribute to 
the increased formation of new vessels in affected RA joints. Thus, MPs serve as novel 
communication devices that contribute to the pathogenesis of RA by inducing an activated 
phenotype in SF with increased release of matrix degrading enzymes, pro-inflammatory 
mediators and pro-angiogenic chemokines.  
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Table 1: Clinical characteristics of RA patients. 
Patient 
number 
Sex Age Rheumatoid  
Factor 
Anti-CCP-
antibodies 
Erosions on  
x-ray 
DAS 28  
Score 
Medication 
1 female 52 + + + 5.3 methotrexate, adalimumab, low dose corticosteroids 
2 female 56 - - + 4.2 methotrexate 
3 male 48 + - + 3.1 adalimumab 
4 female 44 + + + 4.4 methotrexate, etanercept, low dose corticosteroids 
5 female 52 + - + 4.7 adalimumab, low dose corticosteroids 
6 female 39 + + + 5.8 methotrexate, rituximab, low dose corticosteroids 
7 male 54 + - + 3.1 leflunomide 
8 male 51 - + + 4.5 methotrexate, remicade, low dose corticosteroids 
9 female 41 + - + 4.2 methotrexate, adalimumab, low dose corticosteroids 
10 male 32 + - - 3.6 -- 
11 female 46 - - + 3.3 methotrexate, low dose corticosteroids 
12 female 51 + + + 5.7 methotrexate, rituximab 
 
RASF were isolated from patients 1 – 9. MPs from synovial fluid obtained by joint puncture were obtained from patients 10 – 12. All clinical 
characteristics are from the timepoint, when the material was obtained.   
 
 
 
  
 
Table 2: primer sequences 
gene sequence 
CXCL1 
rev 
fwd 
5´- GTC ACT GTT CAG CAT CTT TTC G - 3´ 
5´- CTG CAT CCC CCA TAG TTA AGA A - 3´ 
CXCL2 
rev 
fwd 
5´- ATT TGC CAT TTT TCA GCA TCT T - 3´ 
5´- ATC GCC CAT GGT TAA GAA AAT - 3´ 
CXCL3 
rev 
fwd 
5´- CGG GGG ACC TTA CAT TCA C - 3´ 
5´- GCA TTT AAT TCA CCT CAA GA - 3´ 
CXCL5 
rev 
fwd 
5´- CTA TGG CGA ACA CTT GCA GA - 3´ 
5´- GCA AGG AGT TCA TCC CAA AA - 3´ 
CXCL6 
rev 
fwd 
5´- TCG TTT TGG GGT TTA CTC TCA - 3´ 
5´- GCT GCG TTG CAC TTG TTT AC - 3´ 
 
Figure Legends 
Figure 1: MPs derived from leukocytes potently induce the expression of pro-angiogenic 
chemokines in SFs. Coincubation of RASFs patients with pathophysiologically relevant 
numbers of MPs derived from U937 cell stimulated the expression of the ELR+ CXC 
chemokines CXCL1 (Figure 1a), CXCL2 (Figure 1b), CXCL3 (Figure 1c), CXCL5 (Figure 
1d) and CXCL6 (Figure 1e) in dose dependent manner as analyzed by real-time PCR. * 
indicates statistically significant differences compared to controls (p < 0.05). Comparable 
effects on the expression of ELR+ chemokines were also observed with MPs isolated from the 
synovial fluid of inflamed joints of three different RA patients (Figures 1 f-j).  
 
Figure 2: Supernatants from SFs incubated with MPs are chemotactic for microvascular ECs. 
Supernatants from SFs cocultured with MPs derived from leukocytes stimulated migration of 
ECs. The chemotactic effects can be partially inhibited by blocking antibodies against 
CXCL1, 2, 3, CXCL5 or CXCL6, demonstrating that the increased chemotactic activity is 
mediated by these ELR+ CXC chemokines. * indicates statistically significant differences 
compared to controls (p < 0.05). # indicates statistically significant compared to supernatants 
from SFs coincubated with MPs with irrelevant, non-blocking antibodies (p < 0.05). 
 
Figure 3: Supernatants from SFs coincubated with microparticles do not alter the metabolic 
activity or affect the viability of ECs. Incubation of ECs with increasing concentrations of 
supernatants from SFs cocultured with MPs did not alter the metablic activity as analyzed 
with the MTT assay (Figure 3a). The number of annexin V positive, apoptotic ECs (Figure 
3b) or the number of PI positive necrotic ECs (Figure 3c) also did not change.    
 
Figure 4: Supernatants from SFs cocultured with microparticles stimulate angiogenesis in the 
matrigel plague assay in vivo. For this assay, chambers filled with supernatants from SF 
coincubated with MPs or control supernatants re-suspended in matrigel and chambers were 
implantated into subcutaneous pockets of C57Bl/6 mice. Blood vessels infiltrating into the 
matrigel chamber were quantified after ten days. The number of blood vessels, defined by the 
presence of erythrocytes in the luminal space lined by CD34 positive endothelial cells, 
increased significantly higher in chambers filled with supernatants from SF co-incubated with 
MPs compared to supernatants from SF cultured without MPs. * indicates statistically 
significant differences (p < 0.05).  
 
Figure 5: Microparticles as key-players in the pathogenesis of RA. MPs are released from 
infiltrating leukocytes upon activation and accumulated in the synovial fluid of inflamed 
joints. MPs activate SFs and potently stimulate the release of pro-angiogenic ELR+ 
chemokines, pro-infammatory CC chmokines and matrix degrading enzymes from SFs. 
Aberrant activation of SFs by MPs might therefore directly contribute to hypervascularisation, 
inflammation and joint destruction in RA.   
 
 
